London, UK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading data and analytics provider to the global insurance industry, has announced the launch of the insurance industry’s first Carbon Trust Assured Model for property claims in the UK. The new Verisk Property Claims Carbon Calculator empowers insurers to accurately measure, benchmark and strategise to reduce the carbon footprint for their claims. The innovative new tool supports compliance with Scope 3 emissions reporting and advances ...

Core Viewpoint - Roche has received the EU CE mark for its Port Delivery Platform containing Susvimo, now known as Contivue® in the EU, which allows for continuous delivery of ranibizumab directly to the eye for the treatment of neovascular age-related macular degeneration (nAMD) [1][7]. Company Overview - Roche is focused on developing innovative therapies to combat vision loss, particularly through its advancements in continuous drug delivery systems [10][12]. - The company has a broad pipeline in ophthalmology, including treatments for various retinal diseases [11]. Product Details - Contivue is a refillable eye implant that allows for the delivery of a customized formulation of ranibizumab, with the potential for up to two treatments per year [6][7]. - The device includes four ancillary devices for filling, inserting, refilling, and removing the implant if necessary [1][6]. Clinical Data - Long-term data from the LADDER study indicates that patients treated with Contivue with Susvimo maintained good visual outcomes over seven years, with an average decline of only six letters in best-corrected visual acuity (BCVA) [3][4]. - Approximately 95% of patients maintained the durability of Contivue with Susvimo over the study period [3]. Market Impact - Susvimo is under review with the European Medicines Agency (EMA) and, once approved, will be the first continuous delivery treatment for nAMD, potentially impacting 1.7 million people in the European Union [7]. - The product is already approved in the US for nAMD, diabetic macular edema (DME), and diabetic retinopathy (DR) [9].

Core Points - Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders to September 11, 2025, to allow more time for stockholder participation [1][2] - The Board of Directors recommends voting FOR the proposals in the definitive Proxy Statement filed with the SEC on August 18, 2025 [2] - The company’s lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and utilizes patented ADAPT tissue technology [8] Voting Details - Stockholders who have already voted do not need to take further action as their votes will remain counted [3] - Proxies must be submitted by 11:59 p.m. Eastern time on September 10, 2025, for Internet or telephone submissions, and by the close of business on the same date for mail submissions [4] - CDI holders must direct CDN to vote by 5:00 p.m. Central time on September 9, 2025 [5] Company Overview - Anteris Technologies is a global structural heart company focused on developing medical devices to restore heart function [7] - The company is based in Australia with a significant presence in Minneapolis, USA, and is committed to delivering solutions for structural heart disease [7]

The company previously informed that in March it attracted a strategic investor – Turkish tourism sector businessman and investor Neset Kockar, who manages international aviation, real estate, tourism and other businesses. In April, the first stage of the transaction was successfully completed, during which N. Kockar acquired 23.2% of the company's shares from three individual shareholders. The transaction parties planned to complete the second stage of the transaction by autumn, after which N. Kockar would ...

Core Insights - Viridien and TGS have launched the Megabar Extension Phase I survey in the Barreirinhas Basin, covering 5,300 sq km, aimed at enhancing geological understanding and exploration potential in the region [1][4] - The Barreirinhas Basin is noted for its proven petroleum systems and recent licensing activities by international oil companies (IOCs), indicating a growing interest in the area [2][5] - The survey will utilize TGS's advanced GeoStreamer technology aboard the Ramform Tethys vessel, with data acquisition set to begin in early September and conclude by late November [3] Company Insights - Viridien is a technology and Earth data company focused on providing innovative solutions for natural resource challenges, employing around 3,200 people globally and listed on Euronext Paris [6] - TGS is committed to delivering high-quality data for exploration in Brazil's equatorial margin basins, leveraging its expertise to support the energy industry [5] Industry Insights - The Megabar Extension Phase I survey is positioned in a promising area with no existing 3D data, which could lead to new exploration opportunities and improved prospect evaluation [3][4] - The project is expected to generate significant interest and value for clients, providing them with an early-mover advantage in the underexplored Barreirinhas Basin [5]

Sampo plc, stock exchange release, 4 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 3 September 2025 On 3 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code) 9,1769.55AQEU 111,9689.54CEUX 28,3059.55TQEX 188,2969.55<td style="width:5 ...

Core Viewpoint - Nicox SA anticipates fully repaying its financial debts by 2026, bolstered by the global licensing of NCX 470 and positive results from its Phase 3 clinical trial, Denali [1][2]. Financial Update - The company expects milestone payments from NCX 470 in 2026 and 2027, with royalties on net sales anticipated from 2027 [5]. - Nicox is financed into Q3 2026, with a commitment to cost control and resource optimization [5]. Product Development - NCX 470 has been licensed globally to Kowa and Ocumension Therapeutics, with NDA submissions planned for the U.S. in H1 2026 and subsequently in China [6][10]. - The Phase 3 clinical program for NCX 470 in Japan has been initiated, managed by Kowa [9][10]. Strategic Options - The company is considering future strategic options, including collaborations or business combinations [4][2]. - Glaukos has extended its research agreement for NCX 1728, which is being evaluated for glaucoma and retinal diseases [7]. Market Presence - Nicox's ZERVIATE is commercially available in the U.S. and China through exclusive licensing agreements [8]. - The company has a diverse portfolio, including VYZULTA, which is licensed worldwide to Bausch + Lomb [11].

Core Insights - TGS, in collaboration with Viridien, has launched the Megabar Extension Phase I survey in the Barreirinhas Basin offshore Northern Brazil, covering an area of 5,300 sq km [1][2] - The survey aims to enhance geological understanding and support exploration activities in a region with proven petroleum systems and significant discoveries in nearby basins [2][4] Company Overview - TGS is a global leader in energy data and intelligence, providing advanced data and insights to support exploration and production in the energy sector [6] - The company utilizes cutting-edge technology, including proprietary GeoStreamer technology, to acquire high-quality 3D seismic data [3][5] Industry Context - The Barreirinhas Basin is gaining momentum due to recent licensing activities by international oil companies (IOCs) and the success of Brazil's 5 Cycle Permanent Concession Offer [2] - The Megabar Extension survey is positioned to provide early-mover advantages for explorers in this underexplored area, potentially leading to new exploration opportunities [5]

Group 1 - Ackermans & van Haaren (AvH) supports a Series B financing round of 55 million euros for MRM Health, a clinical-stage biopharmaceutical company focused on microbiome-based therapeutics for inflammatory diseases and immune-oncology [1] - AvH's additional investment in this financing round amounts to 3 million euros, increasing its total investment in MRM Health to 10.8 million euros [1] - AvH's fully diluted participation in MRM Health is now 14.1% following this investment [1]

Core Viewpoint - Voltalia has launched the SPRING transformation plan aimed at driving sustainable and profitable growth by refocusing on core activities, improving operational efficiency, and enhancing profitability [1][4][6] Strategic Drivers - The SPRING plan focuses on four strategic drivers: refocusing on core activities and geographies, clarifying the operating model, improving performance through efficiency and optimization, and enhancing profitability and value creation [3][6][12] - The company aims to self-finance 300 to 400 MW of growth annually from 2026 to 2030, with a target of returning to a positive net result starting in 2026 [1][4][13] Financial Objectives - Voltalia projects medium-term cash inflows of €300 to €350 million mainly between 2026 and 2028, with recurring cash savings expected to reach around €45 million per year from 2026 onwards [8][14] - The company targets an EBITDA of €300-325 million by 2027, with Energy Sales contributing €270-300 million [14][15] - By 2030, the EBITDA margins for Energy Sales are expected to be between 70%-72%, and for Services, between 9%-11% [14][15] Operational Focus - Voltalia plans to concentrate resources on a maximum of twelve promising geographies while exiting non-strategic markets [12] - The company will focus on three priority technologies: Solar, Onshore wind, and Battery storage [12] - A dedicated subsidiary will be created to enhance the competitiveness of construction and maintenance services [12] Long-term Vision - The company aims to achieve a net debt-to-EBITDA ratio of 7.5x to 8.0x by 2030, reinforcing its balance sheet [14][15] - Voltalia is positioning itself to initiate dividend distribution by 2028 [13][14]